Clinical Trial Update: Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the efficacy and safety of grazoprevir and uprifosbuvir with either elbasvir or ruzasvir in chronic Hepatitis C genotypes 1 and 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Elbasvir (elbasvir)
• Grazoprevir (grazoprevir)
• Ruzasvir (ruzasvir)
• Uprifosbuvir (uprifosbuvir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C | Phase 2 | Status: COMPLETED | Results posted: 2017-12-21